The industry is facing challenges from the new administration that could have serious impacts on everything from market ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

New data show that Uzedy significantly reduces relapse and healthcare utilization, while TEV-'749 has demonstrated strong ...

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good ...

Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...

Under terms of the deal, both companies will co-develop and co-commercialize BNT327 for multiple solid tumors, with the ...

The pharmaceutical company will donate money for each strike-out made by the team’s pitcher for the remainder of the regular ...

A Harvard Business School Healthcare Alumni Association Q&A with Aileen Fernandes, Chief Business Officer of Arcellx.

Lilly is also developing oral therapies for its gastroenterology pipeline.

In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster ...